Novartis Q4 Results
↓
↑
Content
Click below to navigate
through the document
Company overview
Novartis pipeline in Phase 2
Oncology
Immunology
INNOVATION
20 lead indications
Lead indication
Financial review
Code
Name
Mechanism
Solid tumors
AAA601
Indication(s)
LutatheraⓇ
Radioligand therapy target SSTR GEPNET, pediatrics
1L ES-SCLC
Glioblastoma
KRAS inhibitor
SHP2 inhibitor
NSCLC and CRC (mono and/or combo)
Solid tumors
Conclusions
Appendix
Innovation: Pipeline overview
Financial performance
Innovation: Clinical trials
Abbreviations
JDQ443 opnurasib
TNO155 TNO155
Hematology
ABL001 ScemblixⓇ
PHE885
BCR-ABL inhibitor
durcabtagene autoleucel BCMA cell therapy
PKC412 Rydapt®
Multi-targeted kinase inhibitor
YTB323
rapcabtagene autoleucel CD19 CAR-T
References
Neuroscience
Code
Name
BLZ945 sotuletinib
DLX3131 minzasolmin
Mechanism
CSF-1R inhibitor
Alpha-synuclein misfolding
inhibitor
Chronic myeloid leukemia, 2L, pediatrics
4L multiple myeloma
Acute myeloid leukemia, pediatrics
1L high-risk large B-cell lymphoma
Indication(s)
Amyotrophic lateral sclerosis
Parkinson's disease
Code Name
CFZ533 iscalimab
DFV890 DFV890
LNA043 LNA043
LOU064 remibrutinib
LRX712 LRX712
MAS825 MAS825
MHV370 MHV370
NG1226 NG1226
QUC398 QUC398
RHH646 RHH646
VAY736 ianalumab
Mechanism
CD40 inhibitor
NLRP3 inhibitor
ANGPTL3 agonist
BTK inhibitor
TLR7, TLR8 Antagonist
ADAMTS5 inhibitor
BAFF-R inhibitor, ADCC-
mediated B-cell depletor
YTB323 rapcabtagene autoleucel CD19 CAR-T
Indication(s)
Sjögren's
Osteoarthritis
Familial cold auto-inflammatory syndrome
Osteoarthritis
Osteoarthritis (combos)
Food allergy
Hidradenitis suppurativa
Osteoarthritis
NLRC4-GOF indications
Sjögren's
Mixed connective tissue disease
Tendinopathy
Osteoarthritis
Osteoarthritis
Autoimmune hepatitis
srSLE/LN
Cardiovascular, Renal and Metabolic
Code
Name
CFZ533 iscalimab
Mechanism
CD40 inhibitor
CFB inhibitor
LNP023
iptacopan
TIN816 TIN816
XXB750 XXB750
ATP modulator
NPR1 agonist
1. DLX313 is the Novartis compound code for UCB0599.
Indication(s)
Lupus nephritis
Lupus nephritis
Acute kidney injury
Hypertension
Heart failure
□ NOVARTIS Reimagining Medicine
Others
Name
Code
IB&GH
KAE609 cipargamin
Mechanism
Indication(s)
LXE408 LXE408
SEG101 AdakveoⓇ
Others
CMK389 CMK389
LNP023 iptacopan
LTP001 LTP001
PfATP4 inhibitor
Proteasome inhibitor
P-selectin inhibitor
IL-18 inhibitor
CFB inhibitor
SMURF1 inhibitor
Malaria, severe
Malaria, uncomplicated
Visceral leishmaniasis
Sickle cell disease, pediatrics
Pulmonary sarcoidosis
¡AMD
Pulmonary arterial hypertension
Idiopathic pulmonary fibrosis
Novartis Q4 Results | January 31, 2024
39View entire presentation